1 Erratum to: Drugs (2014) 74:1701–1707 DOI 10.1007/s40265-014-0285-6
Page 1701, abstract, lines 4–8: The following sentence, which previously read:
It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL).
Should read:
It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukaemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL).
Page 1701, section 1, paragraph 2, lines 5–9: The following sentence, which previously read:
The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukaemia (SLL) who have received at least two other prior therapies [3, 4].
Should read:
The drug has also been granted accelerated approval in patients with relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma (SLL) who have received at least two other prior therapies [3, 4].
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-014-0285-6.
Rights and permissions
About this article
Cite this article
Markham, A. Erratum to: Idelalisib: First Global Approval. Drugs 74, 1839 (2014). https://doi.org/10.1007/s40265-014-0310-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-014-0310-9